ArticleNature chemistry2026
Retention and biosynthesis of diverse nitroarenes in Escherichia coli after combinatorial nitroreductase gene deletions.
Article in Nature chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The instability of nitroaromatic compounds or nitroarenes in the presence of microbial cells has hindered the ability to biomanufacture these industrially and pharmaceutically relevant chemicals. Although nitroreductase (NTR) gene deletions have been linked to nitroarene stability, the extent of this effect is unclear. Here we perform a comprehensive analysis of bacterial NTR activity in cells by engineering strains of Escherichia coli that contain up to 15 knockouts of known and candidate NTR genes. We evaluate the stability of over 20 exogenously supplemented nitroaromatic compounds to wild-type and engineered strains. For several chemistries, such as di-nitro compounds and nitro-aldehydes, our engineered nitroaromatic reductase knockout strains enable retention of compounds. We leverage these tools and insights to improve or enable nitroaromatic compound biosynthesis, including the biocatalytic transformation of an amine precursor to a nitro compound, the biosynthesis of nitrobenzaldehydes and the combined semi-synthesis and site-specific incorporation of nitrophenylalanines from supplemented nitrobenzaldehydes. This work advances access to nitro functional group chemistry in cell-based biocatalysis, metabolic engineering and synthetic biology.
Identifiers
42844378What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.